Iambic Therapeutics (NASDAQ:IAM) Shares Down 4.7% – Time to Sell?

Shares of Iambic Therapeutics, Inc. (NASDAQ:IAM) traded down 4.7% during trading on Wednesday. The company traded as low as $13.96 and last traded at $14.09. 63,777 shares traded hands during trading, a decline of 92% from the average session volume of 754,639 shares. The stock had previously closed at $14.78.

Analysts Set New Price Targets

Several equities analysts have weighed in on IAM shares. Bank of America started coverage on shares of Iambic Therapeutics in a report on Monday. They set a “buy” rating and a $30.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on Iambic Therapeutics in a research note on Monday. They issued an “overweight” rating and a $22.00 price objective on the stock. Citigroup initiated coverage on shares of Iambic Therapeutics in a research report on Monday. They set a “buy” rating and a $22.00 target price on the stock. Jefferies Financial Group started coverage on Iambic Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $35.00 price target for the company. Finally, Wall Street Zen upgraded Iambic Therapeutics to a “hold” rating in a research report on Saturday. Four investment analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $27.25.

Iambic Therapeutics Stock Down 0.2%

Insider Buying and Selling

In related news, Director Evan Lockwood Rachlin bought 718,750 shares of the stock in a transaction dated Friday, October 16th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $11,500,000.00. Following the completion of the purchase, the director directly owned 2,588,248 shares of the company’s stock, valued at $41,411,968. This represents a 38.45% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Iambic Therapeutics Company Profile

Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.